Proteolysis-targeting chimera (PROTAC) and other targeted protein degradation (TPD ... However, the power of PROTACs lies in the engagement of E3 ligases, and currently, less than two percent of the ...

Nerio Therapeutics Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a tyrosine-protein phosphatase non-receptor type 1 ...

Representatives from four leading companies highlight emerging basic and clinical research that drives renewed optimism.

Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting ...

Our group's research efforts aim to uncover novel cancer treatments and centre around three main themes: PROTAC, Molecular Glue Degraders, and novel E3 ligases. My earlier research in PROTAC ...